Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
Go back to Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease| (NASDAQ: RCKT) | Delayed: 3.37 -0.13 (3.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.50 | 52 Week High | $ | |||
| Open | $3.47 | 52 Week Low | $ | |||
| Day High | $3.56 | P/E | N/A | |||
| Day Low | $3.35 | EPS | $ | |||
| Volume | 1,598,193 | |||||
